Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)
Hong Kong
· Delayed Price · Currency is HKD 2.490
+0.040 (1.63%)
Apr 29, 2026, 2:38 PM HKT
HKG:8049 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 901.87 | 881.16 | 841.55 | 841.59 | 705.46 | Upgrade
|
| Revenue Growth (YoY) | 2.35% | 4.71% | -0.01% | 19.30% | 13.37% | Upgrade
|
| Cost of Revenue | 144.2 | 195.91 | 257.5 | 193.55 | 126.19 | Upgrade
|
| Gross Profit | 757.67 | 685.25 | 584.05 | 648.04 | 579.27 | Upgrade
|
| Selling, General & Admin | 561.36 | 522.19 | 448.95 | 509.95 | 453.27 | Upgrade
|
| Other Operating Expenses | -19.11 | -21.57 | -25.55 | -19.91 | -14.63 | Upgrade
|
| Operating Expenses | 542.25 | 500.62 | 423.41 | 490.04 | 438.64 | Upgrade
|
| Operating Income | 215.42 | 184.63 | 160.64 | 158 | 140.63 | Upgrade
|
| Interest Expense | -1.39 | -2.03 | -0.52 | -0.48 | -0.34 | Upgrade
|
| Interest & Investment Income | 48.68 | 18.76 | 33.12 | 35.31 | 33.59 | Upgrade
|
| EBT Excluding Unusual Items | 262.71 | 201.37 | 193.24 | 192.83 | 173.87 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.79 | 5.34 | 5.43 | 4.52 | 3.4 | Upgrade
|
| Asset Writedown | -4.04 | 0.46 | -0.36 | - | - | Upgrade
|
| Pretax Income | 264.46 | 207.16 | 198.31 | 197.35 | 177.27 | Upgrade
|
| Income Tax Expense | 65.58 | 22.91 | 50.11 | 3.78 | 33.99 | Upgrade
|
| Net Income | 198.88 | 184.25 | 148.21 | 193.57 | 143.28 | Upgrade
|
| Net Income to Common | 198.88 | 184.25 | 148.21 | 193.57 | 143.28 | Upgrade
|
| Net Income Growth | 7.94% | 24.32% | -23.43% | 35.09% | 13.21% | Upgrade
|
| Shares Outstanding (Basic) | 560 | 560 | 560 | 560 | 560 | Upgrade
|
| Shares Outstanding (Diluted) | 560 | 560 | 560 | 560 | 560 | Upgrade
|
| EPS (Basic) | 0.35 | 0.33 | 0.26 | 0.35 | 0.26 | Upgrade
|
| EPS (Diluted) | 0.35 | 0.33 | 0.26 | 0.35 | 0.26 | Upgrade
|
| EPS Growth | 7.94% | 24.32% | -23.43% | 35.09% | 13.21% | Upgrade
|
| Free Cash Flow | 300.8 | 208.63 | 284.11 | 192.68 | 122.26 | Upgrade
|
| Free Cash Flow Per Share | 0.54 | 0.37 | 0.51 | 0.34 | 0.22 | Upgrade
|
| Gross Margin | 84.01% | 77.77% | 69.40% | 77.00% | 82.11% | Upgrade
|
| Operating Margin | 23.89% | 20.95% | 19.09% | 18.77% | 19.93% | Upgrade
|
| Profit Margin | 22.05% | 20.91% | 17.61% | 23.00% | 20.31% | Upgrade
|
| Free Cash Flow Margin | 33.35% | 23.68% | 33.76% | 22.89% | 17.33% | Upgrade
|
| EBITDA | 242.63 | 210.65 | 187.09 | 190.43 | 168.72 | Upgrade
|
| EBITDA Margin | 26.90% | 23.91% | 22.23% | 22.63% | 23.92% | Upgrade
|
| D&A For EBITDA | 27.22 | 26.02 | 26.45 | 32.43 | 28.09 | Upgrade
|
| EBIT | 215.42 | 184.63 | 160.64 | 158 | 140.63 | Upgrade
|
| EBIT Margin | 23.89% | 20.95% | 19.09% | 18.77% | 19.93% | Upgrade
|
| Effective Tax Rate | 24.80% | 11.06% | 25.27% | 1.92% | 19.17% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.